Table 2.
The post-treatment values of a specific laboratory stratified by treatment duration.
| 1–7 Days (N = 6) | 14–21 Days (N = 14) | p Value | Effect Size (r) | |
|---|---|---|---|---|
| CHT (nmol/mL/h) post-treatment | 267.50 (176.25, 340.0) | 242.50 (200, 347.50) | 0.772 | 0.064 (s) |
| Neopterin (ng/mL) post-treatment | 0.99 (0.86, 1.11) | 1.15 (1.05, 1.20) | 0.409 | 0.185 (s) |
| NSE (ng/mL) post-treatment | 20.91 (10.82, 47.86) | 26.12 (12.23, 95.57) | 0.409 | 0.018 (s) |
| SCCA (ng/mL) post-treatment | 0.18 (0.02, 0.37) | 0.06 (0.0, 0.10) | 0.269 | 0.303 (m) |
| VDR (ng/mL) post-treatment | 0.33 (0.25, 0.61) | 0.27 (0.09, 0.49) | 0.709 | 0.083 (s) |
| 25OHD3 (nmol/L) post-treatment | 55.74 (53.66, 64.04) | 56.45 (50.16, 64.58) | 1.000 | 0 (s) |
Abbreviations: CHT—chitotriosidase; NSE—neuron-specific enolase; SCCA—squamous cell carcinoma antigen; VDR—vitamin D receptor; 25OHD3—25-hydroxy vitamin D3; data are presented as median and quartiles (Q1-Q3), Mann–Whitney U test. r—effect size; s—small; m—moderate; l—large.